Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
World game at war: why some European nations have threatened a World Cup boycott 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
 and Lead Plaintiff Deadline - May 28, 2018 - EconoTimes)
NEW YORK, May 02, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
